505637437 08/23/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5684243

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GALENICA AB	08/19/2019

RECEIVING PARTY DATA

Name:	ALBIREO AB	
Street Address:	ARVID WALLGRENS BACKE 20	
City:	GÖTEBORG	
State/Country:	SWEDEN	
Postal Code:	413 46	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15449781

CORRESPONDENCE DATA

Fax Number: (877)769-7945

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: +1 (612) 638-5719

Email: enb@fr.com

Correspondent Name: ALYSHA A. DICKE

Address Line 1: FISH & RICHARDSON P.C.

Address Line 2: P.O.BOX 1022

Address Line 4: MINNEAPOLIS, MINNESOTA 55440-1022

ATTORNEY DOCKET NUMBER:	23854-0037001 (G A)
NAME OF SUBMITTER:	ELIZABTH A. BAUER
SIGNATURE:	/Elizabeth A. Bauer/
DATE SIGNED:	08/23/2019

Total Attachments: 4

source=NP0238US_2019-08-21_assignment Galenica to Albireo#page1.tif source=NP0238US_2019-08-21_assignment Galenica to Albireo#page2.tif source=NP0238US_2019-08-21_assignment Galenica to Albireo#page3.tif source=NP0238US_2019-08-21_assignment Galenica to Albireo#page4.tif

PATENT 505637437 REEL: 050150 FRAME: 0011

ASSIGNMENT

Assignor:

GALENICA AB

a corporation organized and existing under the laws of Sweden,

and having a place of business at:

Pär Albin Hanssons väg 41

205-12 Malmö

Sweden

Assignee:

ALBIREO AB

a corporation organized and existing under the laws of Sweden.

and having a place of business at:

Arvid Wallgrens Backe 20

413 46 Göteborg

Sweden

Country	Application No.	Filing Date	Title
United States	15/449,781	3/3/2017	ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF
United States	15/988,281	5/24/2018	ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF
United States	15/988,317	5/24/2018	ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF
WIPO	PCT/SE2017/050127	2/9/2017	ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF

- 1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
- 2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in its own name wherever so permitted by law or in the name of Assignee wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and

PATENT REEL: 050150 FRAME: 0012

Atterney Docket No. 23854-0037001

Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

- 3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
- 4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
- Assignor represents that Assignor has the full right to convey the interests assigned by this
 Assignment, and that Assignor has not executed and will not execute any agreement in conflict
 with this Assignment.
- This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

PATENT REEL: 050150 FRAME: 0013

Attorney Docket No. 23854-0037001

The Assignor hereby executes this Assignment.	
Assignor: GALENICA AB	te lecian.
Signature: 1600 ON	
Name: PORVICE WALLY	
Title: <u>CEO</u>	
Witnessed by:	
Signature: MMUM	Date:
Print Name: EMWA CLUCK	·
Signature: Analysat	
Print Name: Annica Granström	, ,

PATENT REEL: 050150 FRAME: 0014 Assignee: Albirea AB

Signature: Date: Avg 19, 2019

Name: Mattion

Title: Manyaging Director

Witnessed by:
Signature: Param Gillian Date: Avg 19, 2019.

Print Name: Param Gillian Date: Avg 19, 2019.

Print Name: Asa Karlson

The Assignee hereby acknowledges and accepts the foregoing assignment.

61756253.doc

PATENT REEL: 050150 FRAME: 0015

RECORDED: 08/23/2019